{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:32:43Z","timestamp":1794047563456,"version":"4.8.0"},"reference-count":12,"publisher":"Ferrata Storti Foundation (Haematologica)","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2025.300445","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:22:39Z","timestamp":1782890559000},"page":"2199-2201","source":"Crossref","is-referenced-by-count":1,"title":["Metformin: interferon\u2019s new dancing partner?"],"prefix":"10.3324","author":[{"given":"Hans C.","family":"Hasselbalch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"91036","doi-asserted-by":"crossref","unstructured":"Reeves BN, Song J, Leier A. Metformin alleviates side effects and supports the resumption of interferon therapy in polycythemia vera and essential thrombocythemia. Haematologica. 2026; 111(7):2397-2402.","DOI":"10.3324\/haematol.2025.288404"},{"key":"91037","doi-asserted-by":"crossref","unstructured":"Hasselbalch HC, Silver RT. New perspectives of interferon-alpha2 and inflammation in treating Philadelphia-negative chronic myeloproliferative neoplasms. Hemasphere. 2021; 5(12):e645.","DOI":"10.1097\/HS9.0000000000000645"},{"key":"91038","doi-asserted-by":"crossref","unstructured":"S\u00f8rensen AL, Mikkelsen SU, Knudsen TA. Ruxolitinib and interferon-\u03b12 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study. Haematologica. 2020; 105(9):2262-2272.","DOI":"10.3324\/haematol.2019.235648"},{"key":"91039","doi-asserted-by":"crossref","unstructured":"S\u00f8rensen AL, Skov V, Kj\u00e6r L. Combination therapy with ruxolitinib and pegylated interferon-alfa2a in newly diagnosed patients with polycythemia vera. Blood Adv. 2024; 8(20):5416-5425.","DOI":"10.1182\/bloodadvances.2024013170"},{"key":"91040","doi-asserted-by":"crossref","unstructured":"Rehman A, Satyam SM, El-Tanani M. Metformin beyond diabetes: a precision gerotherapeutic and immunometabolic adjuvant for aging and cancer. Cancers. 2025; 17(15):2466.","DOI":"10.3390\/cancers17152466"},{"key":"91041","doi-asserted-by":"crossref","unstructured":"Machado-Neto JA, Fenerich BA, Scopim-Ribeiro R. Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms. Cell Death Dis. 2018; 9(3):311.","DOI":"10.1038\/s41419-017-0256-4"},{"key":"91042","doi-asserted-by":"crossref","unstructured":"Kristensen DT, \u00d8vlisen AK, Jakobsen LHK. Metformin use and risk of myeloproliferative neoplasms: a Danish population-based case-control study. Blood Adv. 2024; 8(16):4478-4485.","DOI":"10.1182\/bloodadvances.2023012266"},{"key":"91043","doi-asserted-by":"crossref","unstructured":"Kristensen DT, Kisbye \u00d8vlisen A, Hjort Kyneb Jakobsen L. Use of statins and risk of myeloproliferative neoplasms: a Danish nationwide case-control study. Blood Adv. 2023; 7(14):3450-3457.","DOI":"10.1182\/bloodadvances.2023009784"},{"key":"91044","doi-asserted-by":"crossref","unstructured":"Davidsen ID, Larsen MK, L\u00f6ffler L. Statins enhance the efficacy of pegylated interferon-alfa2 in Philadelphia-negative chronic myeloproliferative neoplasms. Blood Adv. 2025; 9(23):6189-6198.","DOI":"10.1182\/bloodadvances.2025017016"},{"key":"91045","doi-asserted-by":"crossref","unstructured":"Wu M, Xu H, Liu J. Metformin and fibrosis: a review of existing evidence and mechanisms. J Diabetes Res. 2021; 2021:6673525.","DOI":"10.1155\/2021\/6673525"},{"key":"91046","doi-asserted-by":"crossref","unstructured":"Lee MKS, Cooney OD, Zhu Y. Metformin suppresses atherosclerosis by dampening extramedullary myelopoiesis. Am J Physiol Endocrinol Metab. 2025; 329(3):E420-E432.","DOI":"10.1152\/ajpendo.00056.2025"},{"key":"91047","doi-asserted-by":"crossref","unstructured":"Cimato TR, Palka BA, Lang JK, Young RF. LDL cholesterol modulates human CD34+ HSPCs through effects on proliferation and the IL-17 G-CSF axis. PLoS One. 2013(8):e73861.","DOI":"10.1371\/journal.pone.0073861"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2025.300445\/79520","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2025.300445\/80436","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/13173\/79520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:14:35Z","timestamp":1794046475000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2025.300445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":12,"URL":"https:\/\/doi.org\/10.3324\/haematol.2025.300445","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,19]]}}}